Peter A. Meredith
#166,994
Most Influential Person Now
Peter A. Meredith's AcademicInfluence.com Rankings
Peter A. Meredithphilosophy Degrees
Philosophy
#9876
World Rank
#13497
Historical Rank
Logic
#6829
World Rank
#8380
Historical Rank

Peter A. Meredithbiology Degrees
Biology
#13573
World Rank
#17125
Historical Rank
Biochemistry
#2385
World Rank
#2535
Historical Rank

Download Badge
Philosophy Biology
Peter A. Meredith's Degrees
- Doctorate Medicine Stanford University
Why Is Peter A. Meredith Influential?
(Suggest an Edit or Addition)Peter A. Meredith's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? (1998) (542)
- Clinical Pharmacokinetics of Amlodipine (1992) (220)
- Bioequivalence and other unresolved issues in generic drug substitution. (2003) (205)
- Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. (1999) (120)
- ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. (1998) (110)
- Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man. (1983) (87)
- Long-Term and Ultra Long–Term Blood Pressure Variability During Follow-Up and Mortality in 14 522 Patients With Hypertension (2013) (85)
- A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. (1982) (82)
- A RETROSPECTIVE ANALYSIS OF BLOOD-LEAD IN MENTALLY RETARDED CHILDREN (1977) (81)
- Pharmacokinetics of calcium antagonists. (1988) (78)
- Enalapril Clinical Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships (1993) (72)
- The effect of calcium on lead absorption in rats. (1977) (65)
- CONTRIBUTION OF LEAD IN DRINKING WATER TO BLOOD-LEAD (1977) (65)
- The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. (1988) (64)
- Effects of aluminium, lead and zinc on delta-aminolaevulinic acid dehydratase. (1977) (64)
- Cancer risk of hypertensive patients taking calcium antagonists (1998) (64)
- The effect of captopril on the reflex control heart rate: possible mechanisms. (1985) (62)
- Theophylline-salbutamol interaction: bronchodilator response to salbutamol at maximally effective plasma theophylline concentrations. (1981) (61)
- The percutaneous absorption of lead-203 in humans from cosmetic preparations containing lead acetate, as assessed by whole-body counting and other techniques. (1980) (60)
- Kinetic-dynamic relations and individual responses to enalapril. (1990) (59)
- Delta-aminolaevulinic acid metabolism in normal and lead-exposed humans. (1978) (59)
- Pharmacokinetic overview of doxazosin. (1987) (58)
- Blood pressure variability and its implications for antihypertensive therapy. (1995) (58)
- Immediate cardiovascular responses to oral prazosin—Effects of concurrent β‐blockers (1981) (57)
- Nifedipine: Individual Responses and Concentration‐Effect Relationships (1988) (54)
- Verapamil pharmacokinetics and apparent hepatic and renal blood flow. (1985) (52)
- Phase I and pharmacokinetic study of D-verapamil and doxorubicin. (1991) (52)
- Clinical pharmacological aspects of calcium antagonists and their therapeutic role in hypertension. (1985) (51)
- Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. (2008) (50)
- The Relationships Between Dose and Antihypertensive Effect of Four AT 1 -receptor Blockers. Differences in Potency and Efficacy (2002) (46)
- Clinical pharmacological studies with doxazosin. (1986) (46)
- Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. (1999) (45)
- Pharmacodynamic modeling of the antihypertensive response to amlodipine (1993) (45)
- Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: A literature review comparing amlodipine and nifedipine GITS (2012) (45)
- Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms (2009) (44)
- Combination of Nifedipine and Doxazosin in Essential Hypertension (1992) (44)
- HEPATIC DRUG METABOLISM AND HAEM BIOSYNTHESIS IN LEAD‐POISONED RATS (1978) (43)
- Methodological considerations in calculation of the trough: peak ratio (1994) (43)
- Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. (2004) (42)
- Clinical Pharmacokinetics of Prazosin — 1985 (1985) (42)
- FDA Guidelines on Trough: Peak Ratios in the Evaluation of Antihypertensive Agents (1994) (41)
- Concentration-effect relationships and individual responses to doxazosin in essential hypertension. (1989) (40)
- Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects (1984) (40)
- Prediction of the antihypertensive response to enalapril. (1989) (39)
- Initial blood pressure as a predictor of the response to antihypertensive therapy. (1988) (38)
- Differential Effects of a Missed Dose of Trandolapril and Enalapril on Blood Pressure Control in Hypertensive Patients (1995) (37)
- Review: From Hypertension to Heart Failure — Are There Better Primary Prevention Strategies? (2006) (37)
- Therapeutic implications of drug "holidays'. (1996) (36)
- Erythrocyte delta-aminolaevulinic acid dehydratase activity and blood protoporphyrin concentrations as indices of lead exposure and altered haem biosynthesis. (1979) (35)
- Hematocrit Predicts Long-Term Mortality in a Nonlinear and Sex-Specific Manner in Hypertensive Adults (2012) (34)
- The Effects of Aluminium, Lead and Zinc on δ-Aminolaevulinic Acid Dehydratase (1974) (34)
- Acetaminophen Use and Risk of Myocardial Infarction and Stroke in a Hypertensive Cohort (2015) (34)
- Oral pharmacokinetics of omeprazole (2004) (33)
- Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria. (1977) (32)
- Generic Drugs (1996) (32)
- A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. (1988) (32)
- Angiotensin II Receptor Antagonists Alone and Combined with Hydrochlorothiazide (2005) (31)
- Concentration-effect analysis of antihypertensive drug responses. (1990) (29)
- The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow. (1985) (29)
- The pharmacokinetics of doxazosin in elderly normotensives. (1986) (28)
- Differences between calcium antagonists: duration of action and trough to peak ratio (1993) (28)
- The contribution of drinking water lead to maternal blood lead concentrations. (1979) (28)
- Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. (1996) (28)
- Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 3: Safety, efficacy, tolerability and duration of action (1993) (28)
- Cardiac effects of lead in drinking water of rats. (1975) (26)
- Lead exposure and renal failure: does renal insufficiency influence lead kinetics? (1981) (26)
- British Journal of Clinical Pharmacology (2013) (26)
- A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. (1991) (25)
- A comparative assessment of the duration of action of amlodipine and nifedipine GITS in normotensive subjects. (1993) (25)
- The determination of labetalol in plasma by high-performance liquid chromatography using fluorescence detection. (1981) (25)
- Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. (1985) (24)
- Are fixed-dose combination antihypertensives suitable as first-line therapy? (2012) (24)
- Is Postural Hypotension a Real Problem with Antihypertensive Medication? (2001) (24)
- Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man. (1985) (23)
- Clinical Comparative Trials of Angiotensin II Type 1 (AT 1 )-Receptor Blockers (2001) (23)
- Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. (1984) (23)
- The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects (1987) (23)
- Application of Pharmacokinetic-Pharmacodynamic Modelling for the Comparison of Quinazoline α-Adrenoceptor Agonists in Normotensive Volunteers (1985) (23)
- Kinetics of lead following intravenous administration in man. (1984) (22)
- The combination of prazosin and verapamil in the treatment of essential hypertension (1988) (21)
- Changes in serum aluminium, blood zinc, blood lead and erythrocyte δ-aminolaevulinic acid dehydratase activity during haemodialysis (1979) (21)
- Acetaminophen use and change in blood pressure in a hypertensive population (2013) (21)
- The association between lead concentrations in teeth and domestic water lead concentrations. (1978) (21)
- Clinical Studies with the Potassium Channel Activator Cromakalim in Normotensive and Hypertensive Subjects (1990) (21)
- Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure (2007) (20)
- The effects of industrial lead poisoning on cytochrome P450 mediated phenazone (antipyrine) hydroxylation (1977) (19)
- Trough: peak ratio and smoothness index for antihypertensive agents. (1999) (19)
- Effect of Calcium Channel Blockers on Adrenergic and Nonadrenergic Vascular Responses in Man (1985) (19)
- The storage of samples for blood and water lead analysis. (1977) (19)
- The in vivo effects of zinc on erythrocyte delta-aminolaevulinic acid dehydratase in man (1980) (18)
- Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man. (1993) (18)
- Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. (1987) (17)
- Lead exposure and changes in the renin-angiotensin-aldosterone system in man. (1985) (17)
- Importance of sustained and “tight” blood pressure control in patients with high cardiovascular risk (2016) (17)
- Pharmacokinetic-Pharmacodynamic Relationships of α-Adrenoceptor Antagonists (1989) (17)
- An Evaluation of the Pharmacodynamics and Pharmacokinetics of Nicardipine Combined with Enalapril in Essential Hypertension (1987) (17)
- Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension (2010) (17)
- Action of lead on neurotransmission in rats. (1989) (17)
- Relationship between plasma prazosin concentrations and α‐antagonism in humans: Comparison of conventional and rate‐controlled (Oros) formulations (1988) (16)
- The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol. (1991) (16)
- Effects of lead exposure on rat brain catecholaminergic neurochemistry. (1988) (16)
- Amlodipine; clinical relevance of a unique pharmacokinetic profile. (1993) (16)
- Clinical Pharmacological Studies on the Interaction Between α‐Adrenoceptors and Calcium Antagonists (1985) (16)
- Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. (1999) (16)
- An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. (1992) (16)
- Is cancer related to hypertension or to its treatment? (1999) (15)
- Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril (1992) (15)
- Predictability of antihypertensive responsiveness and α‐adrenoceptor antagonism during prazosin treatment (1989) (15)
- Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why? (1999) (15)
- A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices (2004) (15)
- Clinical relevance of optimal pharmacokinetics in the treatment of hypertension (1997) (15)
- The influence of age on the pharmacokinetics of verapamil. (1991) (14)
- Antihypertensive treatment and trough: peak ratio general considerations (1994) (14)
- Comparison of the Oral Angiotensin II Receptor Antagonist UP 269–6 or Enalapril 20 mg on Blood Pressure and Neurohormonal Effects in Salt‐Deplete Man (1995) (14)
- Controlled‐Release Doxazosin as Combination Therapy in Hypertension: The GATES Study (2006) (14)
- The description and prediction of antihypertensive drug response: an individualised approach. (1991) (13)
- Pharmacokinetics and pharmacodynamics of trimazosin in man. (1983) (13)
- Clinical pharmacology of selective alpha blockers. Hemodynamics and effects on lipid levels. (1987) (13)
- Antihypertensive drugs: individualized analysis and clinical relevance of kinetic-dynamic relationships. (1992) (13)
- Concentration-Effect Analysis of Antihypertensive Drug Response (1994) (13)
- The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension. (1989) (13)
- The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. (1983) (12)
- Erythrocyte Delta‐aminolaevulinic Acid Dehydratase Activity and changes in Delta‐aminolaevulinic Acid Concentration in Various Forms of Anaemia (1978) (12)
- Influence of lead exposure on catecholamine metabolism in discrete rat brain nuclei. (1988) (12)
- The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects (2004) (12)
- A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS) (2013) (12)
- Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the ‘ACTION' database in patients with angina (2010) (12)
- EDITORIAL: Trough peak ratio clinically useful or practically irrelevant? (1995) (11)
- Trough/peak ratios for antihypertensive agents. The issues in perspective. (1994) (11)
- The carcinogenicity of lead (1978) (11)
- Differential effects of ACE inhibiting drugs: Evidence for concentration‐, dose‐, and agent‐dependent responses (1993) (11)
- THE EFFECT OF INDUSTRIAL LEAD POISONING ON CYTOCHROME P-450 MEDIATED PHENAZONE HYDROXYLATION (1977) (10)
- The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. (1991) (10)
- Concentration-effect relationships and implications for trough-to-peak ratio. (1996) (10)
- The determination of trimazosin and its metabolite CP23445 in whole blood by high performance liquid chromatography using fluorescence detection. (1984) (10)
- Zinc, copper and δ-aminolaevulinic acid dehydratase in vitro and in vivo (1981) (10)
- Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. (1996) (10)
- Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans. (1986) (10)
- The Effects of Zinc and Lead on δ-Aminolaevulinate Dehydratase (1978) (10)
- Achieving Quality 24-h Blood Pressure Control with Candesartan Cilexetil (2000) (10)
- Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure (2004) (9)
- DOXAZOSIN,AN a-ADRENOCEPTORANTAGONIST: PHARMACOKINETICSAND CONCENTRATION- EFFECTRELATIONSHIPSINMAN (1983) (9)
- Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists. (1994) (9)
- Dose-response clarification in early drug development. (1991) (9)
- Therapeutic coverage: reducing the risks of partial compliance. (1994) (9)
- Pharmacokinetics of nifedipine. (1985) (9)
- Achieving and Assessing Therapeutic Coverage (2002) (9)
- R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate. (1993) (9)
- Acute hypotensive response to nifedipine added to prazosin (1984) (9)
- The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine. (1991) (9)
- Ketanserin concentration-effect relationships in individual hypertensive patients. (1988) (9)
- Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite (1983) (8)
- Role of trough to peak efficacy in the evaluation of antihypertensive therapy. (1998) (8)
- Efficacy and Tolerability of Long-Term Rilmenidine Treatment in Hypertensive Diabetic Patients (2004) (8)
- Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man (2005) (8)
- The influence of lead on haem biosynthesis and biodegradation in the rat [proceedings]. (1979) (8)
- Improving Blood Pressure Control in Patients with Diabetes Mellitus and High Cardiovascular Risk (2011) (8)
- A clinical pharmacological assessment of doxazosin and enalapril in combination. (1993) (8)
- Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers. (1985) (8)
- Long‐acting calcium antagonists: amlodipine versus nifedipine gastrointestinal therapeutic system (GITS) (1993) (7)
- Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists. (1989) (7)
- A putative placebo comparison of the SCOPE and LIFE trials (2004) (7)
- ACE inhibition and AT1 receptor blockers: efficacy and duration in hypertension (2000) (7)
- Organ protection and optimal blood pressure control. (1995) (7)
- Penetration of enoxacin into lung tissue. (1989) (7)
- Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses. (2012) (7)
- Antihypertensive treatment and trough: peak ratio (1994) (7)
- New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responses. (1994) (7)
- How to evaluate the duration of blood pressure control: the trough:peak ratio and 24-hour monitoring. (1998) (7)
- Trimazosin: Relationships Between Hypotensive Effect, Vascular Responsiveness, and Drug and Metabolite Concentrations (1985) (7)
- Trimazosin in normotensive subjects (1984) (7)
- The Pharmacokinetics of Ramipril in a Group of Ten Elderly Patients with Essential Hypertension (1991) (7)
- Enhancing patients' compliance (1998) (7)
- Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study. (2004) (7)
- The Unique Adalat Story – Nifedipine Gastrointestinal Therapeutic System (2007) (7)
- Labetalol and the Management of Hypertension (1981) (6)
- Analysis of trough:peak ratio and the assessment of anti-hypertensive drug action. (1995) (6)
- Pharmacokinetics of spirapril in renal impairment. (1994) (6)
- An additive or synergistic drug interaction: Application of concentration‐effect modeling (1992) (6)
- Neurohormonal and Blood Pressure Responses to Low-Dose Infusion of an Orally Active Renin Inhibitor, Ro 42-5892, in Salt-Replete Men (1992) (6)
- Efficacy of low-density-lipoprotein lowering with statins (1994) (6)
- EFFECTS OF AGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CARDIOVASCULAR DRUGS: APPLICATION OF CONCENTRATION‐EFFECT MODELING. 3. TRIMAZOSIN (1995) (6)
- Prediction and optimisation of the antihypertensive response to nifedipine. (1994) (6)
- Intrinsically long-acting agents compared with long-acting chronoformulations. (2000) (6)
- A Chronotherapeutic Approach to Effective Blood Pressure Management (2000) (6)
- The pharmacokinetics of bucindolol and its major metabolite in essential hypertension. (1985) (5)
- The Effects of Age on the Pharmacodynamics and Pharmacokinetics of Two Formulations of Verapamil (1989) (5)
- Low-dose verapamil in middle-aged and elderly patients with angina pectoris: No evidence of increased susceptibility to the cardiac effects (1992) (5)
- Calculation of trough-to-peak ratio in the research unit setting. Advantages and disadvantages. (1996) (5)
- Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties. (1984) (5)
- Prediction of response to antihypertensive therapy with enalapril and nifedipine. (1989) (5)
- Pressor responsiveness in essential hypertension and the effects of treatment with an alpha blocker, calcium antagonist or ACE inhibitor. (1989) (5)
- A novel statistical approach for the comparison of analytical methods to measure angiotensin converting enzyme activity, enalaprilat, and benazeprilat. (1993) (5)
- Factors determining the response to calcium antagonists in hypertension. (1988) (5)
- Verapamil and prazosin in essential hypertension: evidence of a synergistic combination? (1987) (5)
- The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin (2004) (4)
- Verapamil pharmacokinetics [letter] (1986) (4)
- V-011 ONCE DAILY NIFEDIPINE: THE FORMULATION DICTATES THE PHARMACO KINETIC CHARACTERISTICS AND THE THERAPEUTIC RESPONSES (2011) (4)
- The Effect of Carbon Monoxide upon Erythrocyte δ-Aminolevulinicacid . Dehydratase Activity (1979) (4)
- Modern strategies in hypertension management (2004) (4)
- The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol. (1991) (4)
- 24 Vascular pressor responses in treated and untreated essential hypertension (1988) (4)
- A clinical pharmacological study of nifedipine and lisinopril alone and in combination. (1987) (4)
- Modelling the pharmacokinetics and pharmacodynamics of trimazosin. (1986) (4)
- THE EFFECTS OF AGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CARDIOVASCULAR DRUGS: APPLICATION OF CONCENTRATION–EFFECT MODELING. 2. ACEBUTOLOL (1995) (3)
- 13 Antihypertensive Response and Individual Concentration-Effect Relationships (1987) (3)
- The effects of lead on the renin-angiotensin system. (1985) (3)
- Angiotensin-receptor blockade, cancer, and concerns. (2010) (3)
- A032: Outcome differences between ACE inhibitor and calcium channel blocker treated hypertensives (2000) (3)
- Assessment of the PKU card as a retrospective index of neonatal blood lead status. (1979) (3)
- Angiotensin II antagonists for hypertension: there are differences in efficacy. (2001) (3)
- Do ace inhibitors reduce mortality in hypertensive patients (1998) (3)
- Verapamil pharmacokinetics. (1986) (3)
- The effect of salbutamol on airways following maximal response to theophylline [proceedings]. (1980) (3)
- Haem biosynthesis and hydroxylation of phenazone during lead intoxication. (1976) (3)
- An evaluation of the use of haem-biosynthetic parameters in the detection of industrial and environmental lead exposure: delta-aminolaevulinic acid and coproporphyrin [proceedings]. (1979) (3)
- The effects of lead on catecholamine metabolism in rat brain regions (1981) (3)
- Is end stage renal disease a common outcome among patients attending a hypertension clinic (2008) (3)
- The importance of sustained blood pressure control. (2000) (3)
- Neurotoxic action of lead: effect on tetrahydrobiopterin metabolism in the rat. (1985) (2)
- Enalapril in essential hypertension: the comparative effects of additional placebo, nicardipine and chlorthalidone. (1987) (2)
- CALCIUM-CHANNEL BLOCKERS AND CANCER. AUTHORS' REPLIES (1996) (2)
- Acute and Chronic Nifedipine in Essential Hypertension: Concentration-Effect Relationships (1987) (2)
- Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: II. Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects. (1991) (2)
- THE EFFECTS OF AGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CARDIOVASCULAR DRUGS: APPLICATION OF CONCENTRATION–EFFECT MODELING. 1. TOLMESOXIDE (1995) (2)
- Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives. (1984) (2)
- Amlodipine--does the effect-time profile directly reflect the concentration-time profile throughout a 24-hour period? (1994) (2)
- The influence of age on the pharmacokinetics and antihypertensive responses to dilevalol. (1990) (2)
- Comments on systematic review of clinical‐ and cost‐effectiveness of candesartan and losartan in hypertension and heart failure (2011) (2)
- OUTCOME DIFFERENCES BETWEEN ACE INHIBITOR AND CALCIUM CHANNEL BLOCKER TREATED HYPERTENSIVE PATIENTS: P3.25 (2000) (2)
- Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. (1988) (2)
- antihistamine andconcentration-ef fect relationship ofebastine inhealthy subjects (1988) (2)
- An Evaluation of the Use of Haem-Biosynthetic Parameters in the Detection of Industrial and Environmental Lead Exposure: Erythrocyte δ-Aminolaevulinate Dehydratase and Blood Protoporphyrin Concentrations (1979) (2)
- Zinc, copper and delta-aminolaevulinic acid dehydratase in vitro and in vivo. (1981) (1)
- The student clinicopathologic conference, a device for the teaching of advanced pathology. (1950) (1)
- Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic system (2016) (1)
- Clinical pharmacological evaluation of calcium antagonists and other drugs modifying myogenic tone in essential hypertension. (1989) (1)
- DO ace inhibitors protect against cancer (1998) (1)
- Hypertension & related disorders (2003) (1)
- Counter-regulatory effects of combined ACE inhibition and calcium antagonism. (1988) (1)
- Comparison of medroxalol and labetalol, drugs with combined a- and ,8-adrenoceptor antagonist properties (2006) (1)
- Efficacy of low-density-lipoprotein lowering with statins. (1994) (1)
- Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine. (1984) (1)
- Thrapeutic equivalence in the treatment of hypertension: Can lercanidipine and nifedipine GITS be considered to be interchangeable? (2014) (1)
- Trough/Peak Ratios for Antihypertensive Agents (1994) (1)
- Evaluation of an antihypertensive therapy utilising meta-analysis of a clinical trial database. (2000) (1)
- Factors determining the response to angiotensin-converting enzyme inhibitors in hypertension. (1990) (1)
- Drug safety (2007) (1)
- An evaluation of the use of haem-biosynthetic parameters in the detection of industrial and environmental lead exposure: erythrocyte delta-aminolaevulinate dehydratase and blood protoporphyrin concentrations. [proceedings]. (1979) (1)
- The effects of zinc and lead on delta-aminolaevulinate dehydratase [proceedings]. (1978) (1)
- Do pharmacologic differences among antihypertensive agents point to clinical benefits? (1999) (1)
- Clinical Pharmacokinetics of Nifedipine (1997) (1)
- Acuteandchronic ketanserin inessential hypertension: antihypertensive mechanisms andpharmacokinetics (1987) (1)
- Calculation of Trough-to-Peak Ratio (1996) (1)
- The relationships between initial blood pressure and the response to different antihypertensive agents. (2007) (1)
- The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man. (1992) (1)
- An efficacy and safety study of doxazosin gastrointestinal therapeutic system as combination therapy in hypertensive patients (2004) (1)
- Effect of lead on tetrahydrobiopterin levels in rat brain (1985) (1)
- 9C.08: HEART RATE AS A PREDICTOR OF CARDIOVASCULAR OUTCOMES NEW EVIDENCE FROM THE ACTION TRIAL DATABASE (2015) (0)
- A comparative assessment oftheduration ofaction of amlodipine andnifedipine GITSinnormotensive subjects (1993) (0)
- Benefits of nifedipine GITS in stable coronary artery disease: Further analysis of the “ACTION” database (2009) (0)
- Cardiovascular outcomes after first-ever treatment of hypertension with angiotensin converting enzyme inhibitors or calcium channel-blockers in primary care (2003) (0)
- Exclusion of non-responses (1996) (0)
- Concentration-effect relationships and antihypertensive mechanisms: ketanserin in the treatment of essential hypertension. (1990) (0)
- Therapy in the elderly hypertensive (2002) (0)
- Bioavailability study of a concentrated suspension of phenytoin in healthy volunteers (1992) (0)
- Introduction (2001) (0)
- Alterations of dihydropteridine reductase activity by lead (1985) (0)
- Introduction (2001) (0)
- Review article Are fixed-dose combination antihypertensives suitable as first-line therapy? (2012) (0)
- Cancer risk in hypertensive patients treated with calcium channel blockers (1998) (0)
- Comparison oftheclinical pharmacokinetics andconcentration- effect relationships formedroxalol andlabetalol (1984) (0)
- Antihypertensive treatment: full 24 hour control and trough to peak ratio. (1999) (0)
- Measurement of Trough Blood Pressure (1996) (0)
- A062: Steady state PK of doxazosin GITS versus doxazosin standard and the potential benefits of GITS in the treatment of hypertensive patients (2000) (0)
- Thepharmacokinetics ofdoxazosin inelderly normotensives (1986) (0)
- C-001 EFFECTS OF LONG ACTING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS ON SYMPATHETIC ACTIVITY IN HYPERTENSION: A COMPARISON OF AMLODIPINE AND NIFEDIPINE GITS (2011) (0)
- Reports of Societies (1982) (0)
- Concentration-effect relationships for antihypertensive drugs (1998) (0)
- More drugs and better blood pressure control lead to improved cardiovascular outcomes: evidence from the ACTION database (2013) (0)
- P-485: High pulse pressure does not predict cardiovascular mortality in a general population of hypertensives (2003) (0)
- Wednesday May 28, Ballroom C, 12:00 pm Achieving Comprehensive Hypertension Management: Trough peak ratios: Are there differences between antihypertensive drugs? (1997) (0)
- Adimolol, a long acting beta-adrenoceptor blocker in man. (1987) (0)
- Adimolol, a long acting 3-adrenoceptor blocker in man prolonged 13-adrenoceptor antagonism (2006) (0)
- P-172: A placebo-controlled comparison of the effects of doxazosin GITS 4mg and doxazosin standard 1mg on blood pressure and heart rate (2005) (0)
- Evaluation of endpoints in hypertension: blood pressure. (1997) (0)
- A COMPARATIVE ANALYSIS OF LERCANIDIPINE AND AMLODIPINE IN THE MANAGEMENT OF HYPERTENSION: PP.15.409 (2011) (0)
- Kinetic‐dynamic relationships and antihypertensive mechanisms of ketanserin in essential hypertension (1988) (0)
- Acute Versus Chronic Dosing Studies (1996) (0)
- The effect of carbon monoxide upon erythrocyte delta-aminolevulinicacid dehydratase activity. (1979) (0)
- A PHARMACODYNAMIC AND PHARMACOKINETIC ASSESS- MENT OFA NEW a-ADRENOCEPTORANTAGONIST,DOXAZOSIN (UK33274) INNORMOTENSIVE SUBJECTS (1982) (0)
- Responsiveness to Calcium Antagonists in Essential Hypertension: Pharmacokinetic and Neurohumoral Aspects (1989) (0)
- DOXAZOSIN GASTROINTESTINAL THERAPEUTIC SYSTEM AS COMBINATION THERAPY IN HYPERTENSIVE PATIENTS: AN EFFICACY AND SAFETY STUDY (GATES) (2004) (0)
- Pharmacology of non-compliance (1997) (0)
- Drug safety (1993) (0)
- 3.6 Cancer risk and use of calcium antagonists for hypertension (1997) (0)
- Clinical pharmacological studies with the vasodilator endralazine in patients with renal impairment (2004) (0)
- A PUTATIVE PLACEBO COMPARISON OF THE SCOPE AND LIFE TRIALS: OP 083 (2004) (0)
- The physiologically realistic characterisation of benazeprilat pharmacokinetics in young and elderly volunteers (1990) (0)
- BLOOD PRESSURE CONTROL & CARDIOVASCULAR OUTCOME IN CORONARY ARTERY DISEASE: EVIDENCE FROM THE ACTION TRIAL: 6C.06 (2011) (0)
- A dose-ranging study ofUK-68,798, anovel class III anti-arrhythmic agent, innormal volunteers (1991) (0)
- G-006 CARDIOVASCULAR OUTCOMES IN HYPERTENSIVES TREATED EXCLUSIVELY WITH NIFEDIPINE GITS OR CO-AMILOZIDE: EVIDENCE FROM THE “INSIGHT” DATABASE (2011) (0)
- PROGNOSTIC VALUE OF BLOOD PRESSURE IN PATIENTS WITH CORONARY ARTERY DISEASE: EVIDENCE FROM THE ACTION TRIAL DATABASE: 9A.05 (2010) (0)
- Serum uric acid and stroke in hypertension: Influence of gender (2007) (0)
- The Pharmacokinetics and Pharmacodynamics of Verapamil in Elderly Hypertensives (1988) (0)
- Therapy in the elderly hypertensive (2002) (0)
- PHARMACOKINETICS OF DOXAZOSIN GASTROINTESTINAL THERAPEUTIC SYSTEM (DOX GITS) VERSUS DOXAZOSIN STANDARD: POTENTIAL BENEFITS OF DOX GITS IN THE TREATMENT OF PATIENTS WITH HYPERTENSION (2000) (0)
- Cross-over versus sequential study design (1996) (0)
- ACE INHIBITORS AND OUTCOME IN TREATED HYPERTENSIVE PATIENTS: P3.229 (2000) (0)
- Efficacy and safety of long-acting nifedipine (GITS) in patients with diabetes and symptomatic stable angina pectoris: insights from the ACTION trial (2009) (0)
- Is it time to review the treatment strategies in hypertension guidelines (2009) (0)
- The effect of cimetidine on the pharmacokinetics, pharmacodynamics and alpha1-adrenoceptor responsiveness of trimazosin in man (2004) (0)
- Concentration Effect Analysis of the Prazosin Derivatives, Trimazosin and Doxazosin (1982) (0)
- G-015 PROGNOSTIC VALUE OF BLOOD PRESSURE AND “EARLY” BLOOD PRESSURE CONTROL IN PATIENTS WITH CORONARY ARTERY DISEASE: EVIDENCE FROM THE “ACTION” DATABASE (2011) (0)
- Paroxysmal tachycardia, low nodal in origin, benefited by cardiac sympathectomy. (1948) (0)
- Insights in the Management of Hypertension: Focus on Amlodipine (2001) (0)
- Patient compliance. (1992) (0)
- The effect of food on the pharmacokinetics and pharmacodynamics of tolmesoxide in essential hypertensives (2004) (0)
- A PHARMACODYNAMIC AND PHARMACOKINETIC ASSESS- MENT OFANEWa-ADRENOCEPTOR ANTAGONIST, DOXAZOSIN (UK33274) IN NORMOTENSIVE SUBJECTS (2006) (0)
- Letter: Antipyrine half life and clearance in clinical practice. (1976) (0)
- Evolving strategies in cardiovascular care: The renin-angiotensin system and the future - Discussion (2000) (0)
- Achieving quality 24-h blood pressure control with candesartan cilexetil. (2000) (0)
- Angiotensin II receptor antagonists: new paradigms in the treatment of hypertension. Introduction. (2001) (0)
- Pharmacokinetics of endralazine (2004) (0)
- PHARMACOLOGY OF A CALCIUM T-CHANNEL SELECTIVE BLOCKER (1997) (0)
- A031: ACE inhibitors and outcome in treated hypertensive patients (2000) (0)
- Abstract W P165: Acetaminophen Use and Risk of Stroke and Myocardial Infarction in a Hypertensive Population (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Peter A. Meredith?
Peter A. Meredith is affiliated with the following schools: